I'm with you Drano. Here's a quick discussion I had this

New Post Public Reply Private Reply Replies (2) Message Board
BooDog Drano #15685
I'm with you Drano. Here's a quick discussion I had this morning. Many mentioned here but mainly CTIX and AVXL. Also still seeing sunsplat on the ctix board, relentless misrepresentation trying to implant BS.

Quote:
The manipulation is unreal. 123tom mentioned a few and a group I hang with that primarily shorts stocks (I'll explain more in a bit) reminded me of a couple others, UQM and MDBX. Stocks that get a MAJOR spike and then crash right back down. We've seen some others just this year. I don't short, but it can be done the right way without torturing or being malicious ~ the way it was meant to be. My other group is BP Rising, they simply peg the resistance and cover on the support. Not being greedy like some of the hedge funds or groups like Adam F. Helps me too sometimes, when they start covering and support is confirmed, I can go long again with a bit more confidence. Most of their plays are out of my price range or I hardly seem to have the funds available at the right time.

AVXL wasn't much different as far as the spike went, a lot of hype driving it so many knew the peak wouldn't be sustainable. I like and I use the same strategy gfp927z (what is that ID short for?)...

Quote:

But there is a way to own bio stocks for the longer haul, instead of merely trading them. You can have small positions in a group of favorites and just let them ride for as long as their fundamentals continue to look good. That's how successful private equity outfits like the Baker Bros do it. Another approach is to have a core position and a trading position. For myself I'm content to just follow them out of general interest and for the entertainment value. If I decide to actually invest money again, the strict limit will be $1000 per stock. With this approach you won't get rich, but you'll stay out of trouble.




I have been consistently using both. Light positions in a stock and then loading back up when the chart says to or well ahead of a catalyst and then taking some off around the event or pulling a stop loss if need be. MSTX has been in a sideways range for some time but also has a couple nice catalysts, one soon (by mid December?) and then more on their EPIC study 1q 2016. Took some back off around .43 since the technical weakened but looking to add back on it. ATNM CBAY SYN CTIX CRBP I've been doing the same thing. Took some profits from AVXL and loaded CBAY just in time for it to pull back on me, reminding me not to be so quick to follow the intraday when I'm looking for a longer term swing.
Speaking of intradays, AVXL, 2 days in a row screwed me over, the only thing that saved me from adding back in was the lack of confirmation. Crowin had it right both times on the AVXL thread, I don't follow him and think he may be more of a short but I do try and keep an open mind and not just ignore other ideas. I'm just another rock in the pond so if I see something that might give me an edge I'll take heed and at least be a bit more cautious. I was looking for the 200 dma to hold up better but the low float adds to this volatility. The intraday was showing signs of forming a falling wedge reversal from the daily. My idea was to combine the daily and throw in the intraday, I also mentioned in my post that we'd need to see confirmation. My wedge fell apart shortly after I posted. Is it just shorts? It could be, I didn't see any insider selling. Though I am missing a little over 300K shares post split from the form 5 annual statement and my calculations of the form 4's pre split. Too many posts to go through to see if anyone else addressed that or even caught it. When buyers are staying away or longs are just sitting tight, whatever action there is causing so much volatility but the overall trend is manipulated down because (IMO) hedge funds are whacking out the bid. I think there is institutional interest and whoever it is doing what they can to get whatever they can as low as they can. We'll find out in Jan early Feb when the new numbers come out. Like CTIX, we should see the interest continue so money will be watching. Just need to see if Anavex has something up their sleeve to spark things in the right direction. I'm putting AVXL on early pincher radar soon but it needs to set up a bit more. Divergence still looks a bit weak. Starting to head into the oversolds.
I do like your strategy Gfp927z, have some AVXL in the $4's and looking to load up.
News on ATNM as well so may be able to play that into adding on AVXL. BTW, AVXL on S Ttwits now has over 2013 followers.




Quote:

gfp927z Wednesday, 11/18/15 09:58:04 AM
Re: BooDog post# 1048
Post # of 1049


BooDog, With AVXL they're using the usual shorting techniques like forcing down the bid, but other than the brief Feuerstein article there wasn't a huge accompanying hit piece of the type that happened with CTIX, where they not only trash in great detail the science, but also the CEO and other management's dubious history. The CTIX hit job took months to plan and was a major production, in contrast to AVXL which looks like a one time 'short and move on' opportunity for the short crowd.

AVXL just got way ahead of itself on the upside, having a $500 mil market cap based on a tiny open label Phase 2a. The CEO Missling is a straight arrow compared to Erlich of CTIX, so there wasn't the required ammo for a full fledged long term assault on the stock, in contrast to CTIX. So I'm figuring the AVXL shorts will cover and move on to their next prey and leave the stock alone to gradually recover.

The clinical evidence of efficacy is very early, but AVXL is a potential lotto stock due to the extreme lack of effective Alzheimer's treatments - there are none. The ACHase inhibitors like Aricept, and the NMDA inhibitor Namenda, are basically worthless, but have racked up many billions in sales only because there is no other treatment available. As long as that's the case, interest in AVXL will return. According to Dr. Tracy of NeuroPerspective, AVXL's approach (Sigma-1 receptor) is getting renewed interest in the pharma world. So AVXL has potential as a high risk longer term lotto stock, with a solid CEO in Missling and a $50 mil financing arrangement in place.


Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

CELSET Unveils SOLTOX: Expanding in Global Markets

Updated Category News Views 73

New Contender in the Global Botulinum Toxin Arena Launching a fresh player onto the international stage, CELSET INC. from Seoul throws down with SOLTOX, their own botulinum toxin Type A brand. This ain't your run-of-the-mill roll-out; it's another notch for Korean biotech trying to snag a piece of global market action. A Look at SOLTOX's Technical Makeup We’re talking...

Continue Reading
Banco Macro S.A. Plans $160B Share Buyback Initiative

Updated Category News Views 24

Tapping into Share Buybacks in a Tumultuous Market Out of nowhere, Banco Macro S.A. has decided to whip up a share buyback program, a lifeline for their current market value. Let me tell you, the market's more volatile than a caffeinated squirrel these days, hitting the financial scenery harder than a hammer on a glass table. So, Banco Macro's taken a deep breath and...

Continue Reading
Enertech's New Moves Aim to Make Geothermal Mainstream

Updated Category News Views 74

Breaking Through Financial Barriers in Geothermal Energy Finally, we're seeing some real movement in the geothermal heat pump sector. The longtime hurdles that kept ground-sourced heating and cooling tech at arm's length from the everyday homeowner are starting to tumble, thanks to Enertech Global's latest initiatives. Enertech's Double Deal: A New Lease on Geothermal...

Continue Reading
Agrochemicals: Combining Tradition and Innovation

Updated Category News Views 69

The Evolving World of Agrochemicals You know, the agrochemical market isn't just about fertilizers and pesticides anymore. It's evolving into a high-stakes game of innovation, resistance management, and cutting-edge tech. This whole sector's forecast to explode to a whopping US$ 387.7 billion by 2031. That's no small potatoes. Driving Forces: Pests, Drones, and Regulatory...

Continue Reading
Insurify's AI Gateway: A New Era in Insurance Shopping

Updated Category News Views 66

Insurify's Game-Changing AI Agent Gateway In the insurance world, Insurify's latest move feels like a bull charging through a ticker tape parade. This Cambridge-based pioneer unveiled its AI Agent Gateway, aiming to put consumers back in the driver's seat. By connecting digital assistant agents to its platform, Insurify's making insurance shopping a bit less like pulling...

Continue Reading
Royce Micro-Cap Trust: Navigating Small-Cap Waves

Updated Category News Views 42

Folks, if there's ever been a niche in this labyrinth of stocks, it’s the micro-cap territory. Royce Micro-Cap Trust (NYSE: RMT) is hefting the torch for smaller companies up to a billion in market cap. But is it leading the charge or getting steamrolled by market bear crawls? Understanding the Numbers Time to get dirty with some numbers, because for Royce Micro-Cap...

Continue Reading
Pave and Levels.fyi Unite: Revolutionize Pay Decisions

Updated Category News Views 99

Diving straight into the heart of it, here's a move in the business world that's all but marking its territory on the compensation landscape. Pave, already a big player in agentic compensation management, is shaking hands with Levels.fyi, a platform prized for its real-deal compensation data detailed down to the company, level, location, and skill. These folks are...

Continue Reading
Innovative Trial Targets Drug Resistance in Lung Cancer

Updated Category News Views 68

The Battle Against Drug Resistance Heats Up Folks, we're in a never-ending fight here against one of the toughest adversaries out there: lung cancer. And lemme tell ya, when drugs show resistance, it's like trying to punch a ghost. But there’s a fresh wind blowing, as Dr. Bobak Parang steps up to the plate with a $620K grant aimed squarely at tackling drug resistance in...

Continue Reading
Photocure's Q3 2026: Revenue Plateau and CFO Shakeup

Updated Category News Views 111

The Bladder Cancer Scene: Steady as She Goes Sometimes, you look at numbers and find tranquility, like staring into still waters. That's the scene over at Photocure ASA with their latest Q3 results. Clocking in with revenues of NOK 134.2 million from their Hexvix®/Cysview® products, they're barely flinching from last year's NOK 134.1 million. Is it a victory or a...

Continue Reading
Royce Small-Cap Trust Shows Resilience Amid Volatility

Updated Category News Views 95

A Closer Look at Royce's Latest Moves Royce Small-Cap Trust (NYSE: RVT), the venerable old timer in the small-cap fund world, has been trucking along the market's bumpy byways since forever ago. With over 50 years of small- and micro-cap investment experience under its belt, you'd think it might have seen everything by now. But in the volatile world of small caps,...

Continue Reading

Top 5 Most Recently Viewed Articles

Gen Z Hacks Loyalty Programs with AI Power Play

Updated Category News Views 15

Gen Z Leads the Charge in AI-Driven Loyalty The times, they are a-changin', and loyalty programs aren't immune. Hopping on the AI bandwagon, 64% of Gen Z in the UK and 55% in the US are getting more bang for their buck, utilizing AI to optimize their participation and rake in rewards. According to Comarch's latest findings, these young savants aren't just after luxury...

Continue Reading
SendCutSend Triumphs in American Business Awards with Gold

Updated Category News Views 302

SendCutSend Wins Gold Stevie Award at American Business Awards SendCutSend has received a significant honor by winning a coveted Gold Stevie Award in the Manufacturing category during the American Business Awards. This prestigious award program recognizes excellence in various sectors across the country. The awards attracted over 3,600 submissions from multiple...

Continue Reading
Explore the Glow Up Golden Calendar for 2026 Launch

Updated Category News Views 393

Glow Up Golden 2026 Calendar Unveiled at Pearl River Mart -Inspired by ancient Chinese timing to support modern decision-making- In a vibrant new partnership, Julie Huang, renowned writer and Chinese metaphysics practitioner, is set to launch the Glow Up Golden 2026 Calendar at Pearl River Mart. This culturally enriching calendar draws on classical Chinese wisdom, making...

Continue Reading
Luminar Technologies Faces Lawsuit: Investors Take Action

Updated Category News Views 278

Investors Encouraged to Act on Luminar Technologies Lawsuit The focus is now on Luminar Technologies, Inc. (NASDAQ: LAZR) as the opportunity arises for investors to join a significant class action lawsuit. This comes in light of recent allegations of securities fraud within the company. Investors who purchased Luminar securities within the specified time frame are urged...

Continue Reading
Understanding Recent Trends in Catalyst Pharmaceuticals' Short Interest

Updated Category News Views 176

Recent Trends in Catalyst Pharmaceuticals' Short Interest Catalyst Pharmaceuticals (CPRX) has seen a notable increase in its short percent of float, jumping by 5.8% since the last report. The latest figures indicate that about 8.17 million shares are currently sold short, representing 8.57% of all shares available for trading. Based on trading volume, it would take...

Continue Reading